Top Research Presented At The 2021 San Antonio Breast Cancer Symposium Breastcancer.org podcast

コンテンツは Caroline Durham によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Caroline Durham またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

Breastcancer.org Podcast »
Top Research Presented at the 2021 San Antonio Breast Cancer Symposium

2+ y ago 10:00

MP3•エピソードのホーム

アーカイブされたシリーズ ("無効なフィード" status)

When? This feed was archived on April 01, 2022 06:22 (2y ago). Last successful fetch was on February 28, 2022 07:18 (2y ago)

Why? 無効なフィード status. サーバーは持続期間に有効なポッドキャストのフィードを取得することができませんでした。

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Dr. Sara Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers at the Dana-Farber Cancer Institute, as well as associate professor of medicine at Harvard Medical School. The 2021 San Antonio Breast Cancer Symposium featured four days of presentations on the latest research on breast cancer. Dr. Tolaney joined us to discuss the research that is most immediately applicable to people who’ve been diagnosed with the disease. Listen to the episode to hear Dr. Tolaney explain: results of an early study looking at how effective the experimental medicine datopotamab deruxtecan was in treating metastatic, triple-negative breast cancer a study comparing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) to Kadcyla (chemical name: T-DM1 or ad-trastuzumab emtansine) for metastatic, HER2-positive breast cancer that had spread to the brain the studies that she thinks are practice-changing Running time: 10:00

215 つのエピソード